Genocea Biosciences (GNCA) Misses Q1 EPS by 11c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.46), $0.11 worse than the analyst estimate of ($0.35).

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c